These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 186178)

  • 1. An immunoelectron microscopic analysis of Epstein-Barr virus-associated complement-fixing antigen.
    Shamoto M; Suzuki I
    Cancer; 1976 Nov; 38(5):2057-64. PubMed ID: 186178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between Epstein-Barr virus-determined complement-fixing antigen and nuclear antigen detected by anticomplement fluorescence.
    Klein G; Vonka V
    J Natl Cancer Inst; 1974 Dec; 53(6):1645-6. PubMed ID: 4373574
    [No Abstract]   [Full Text] [Related]  

  • 3. Separation of the complement-fixing and early antigens from Epstein-Barr soluble antigen.
    Wainwright WH; Veltri RW
    J Natl Cancer Inst; 1977 Apr; 58(4):1111-3. PubMed ID: 66320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New method for detecting Epstein-Barr virus association in nonproducer lymphoblastoid cell lines.
    Giunta S; Groppa G
    Cancer Res; 1983 Nov; 43(11):5064-7. PubMed ID: 6311404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Epstein-Barr virus antigens. I. Biochemical analysis of the complement-fixing soluble antigen and relationship with Epstein-Barr virus-associated nuclear antigen.
    Lenoir G; Berthelon MC; Favre MC; de-Thé G
    J Virol; 1976 Feb; 17(2):672-4. PubMed ID: 176436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Epstein-Barr virus (EBV) antigens II. Detection of early antigen (S) using anticomplement immunofluorescence (ACIF) et complement fixation (CF) tests.
    Lenoir G; Berthelon MC; Favre MC; De-Thé G
    Biomedicine; 1975 Dec; 23(10):461-4. PubMed ID: 177116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocytochemical detection of antibodies to Epstein-Barr virus nuclear antigen by a streptavidin-biotin-complex assay.
    Musiani M; Zerbini M; Plazzi M; Gentilomi G; La Placa M
    J Clin Microbiol; 1988 May; 26(5):1005-8. PubMed ID: 2838499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble complement fixing antigens in Epstein-Barr virus cell systems.
    Twardzik DR; Ablashi DV; Easton JM; Armstrong GR
    Bibl Haematol; 1975 Oct; (43):412-6. PubMed ID: 183710
    [No Abstract]   [Full Text] [Related]  

  • 9. Purification of soluble complement-fixing antigens from two Burkitt's lymphoma cell lines. Conditions affecting the stability and recovery of antigens and antibodies.
    Weliky N; Leaman DH; Kallman BJ
    Immunology; 1975 Oct; 29(4):779-90. PubMed ID: 241721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a purified complement-fixing antigen as the Epstein-Barr-virus determined nuclear antigen (EBNA) by its binding to metaphase chromosomes.
    Ohno S; Luka J; Lindahl T; Klein G
    Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1605-9. PubMed ID: 67603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localization and quantitation of EBV-associated nuclear antigen (EBNA) in Raji cells.
    Bahr GF; Mikel U; Klein G
    Beitr Pathol; 1975 May; 155(1):72-8. PubMed ID: 168861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between Epstein-Barr virus nuclear antigen and DNA genome number in superinfected and induced lymphoblastoid cell lines.
    Boguszaková L; Hirsch I; Brichácek B; Vonka V
    J Gen Virol; 1983 Apr; 64 (Pt 4)():887-94. PubMed ID: 6300308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of SV40 tumour antigen and Epstein-Barr-virus nuclear antigen to isolated acid-fixed nuclei.
    Suchánková A; Hirsch I; Vonka V
    Acta Virol; 1980 Mar; 24(2):114-8. PubMed ID: 6107019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic identification of Epstein-Barr virus early antigen in a P3HR-1 cell extract.
    Veltri RW; Wainwright WH; Sprinkle PM
    J Natl Cancer Inst; 1976 Aug; 57(2):245-53. PubMed ID: 187767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of soluble antigen of Epstein-Barr virus by the enzyme-linked immunosorbent assay.
    Wallen WC; Mattson JM; Levine PH
    J Infect Dis; 1977 Oct; 136 Suppl():S324-8. PubMed ID: 198494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
    Fresen KO; zur Hausen H
    Proc Natl Acad Sci U S A; 1977 Jan; 74(1):363-6. PubMed ID: 189313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between Epstein-Barr virus-associated nuclear antigen and cell viability in human cell lines.
    Suzuki M; Hinuma Y
    Gan; 1975 Feb; 66(1):103-5. PubMed ID: 168112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demonstration of EBNA (Epstein-Barr virus nuclear antigen) antibodies of different immunoglobulin classes.
    Czeglédy J; Gergely L; Váczi L; Szalka A
    Acta Microbiol Acad Sci Hung; 1978; 25(4):237-43. PubMed ID: 224651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen-inducing ability of herpesvirus papio in human and baboon lymphoma lines, compared to Epstein-Barr virus.
    Klein G; Falk L; Falk K
    Intervirology; 1978; 10(3):153-64. PubMed ID: 210135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early nasopharyngeal carcinoma among IgA/VCA antibody positive individuals detected by anticomplement immunoenzymatic method.
    Zeng Y; Shen SJ; Deng H; Ma JL; Zhang Q; Zhu JS; Cheng JR
    Chin Med J (Engl); 1984 Mar; 97(3):155-7. PubMed ID: 6088182
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.